Andrew Naumoff
Family Medicine · Orrville, OHNPI 1366520785
Payments from drug & device makers
Across 79 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$230
- Novo Nordisk$196
- Amgen$131
- Lilly USA, LLC$87
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
- Sanofi-aventis U.S. LLC$57
- plus $448 from 18 others
What the payments were for
- Food & beverage$1,235100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $230 |
| Novo Nordisk | 17 | $196 |
| Amgen | 5 | $131 |
| Lilly USA, LLC | 6 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Novartis | 3 | $53 |
| Amarin Pharma, Inc. | 4 | $51 |
| Genentech USA, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Shire North American Group Inc | 2 | $27 |
| Johnson & Johnson | 2 | $27 |
| GSK | 2 | $27 |
| Pfizer | 2 | $25 |
| Medtronic | 1 | $23 |
| AstraZeneca | 2 | $22 |
| Abbott | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
| Next Science LLC | 1 | $13 |
| Bsn Medical Inc | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$1,235 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $35,322 |
| TrulicityDulaglutide | 23 | $22,202 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $19,743 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 31 | $9,701 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,579 |
| InvokanaCanagliflozin | 25 | $7,428 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 26 | $6,511 |
| JardianceEmpagliflozin | 17 | $5,188 |
| Divalproex Sodium | 91 | $4,712 |
| Memantine Hcl | 94 | $4,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $3,892 |
| Mirtazapine | 91 | $3,868 |
| Budesonide EcBudesonide | 14 | $3,855 |
| Atorvastatin Calcium | 187 | $3,330 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $2,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $25 | $45,023126 claims |
| Lilly USA, LLCTrulicity | $87 | $22,20223 claims |
| Johnson & JohnsonInvokana | $27 | $7,42825 claims |
| Boehringer IngelheimJardiance | $36 | $5,18817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Orrville
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.